MANKIND PHARMA LTD’s Post

Cardinal Health, a distributor of pharmaceuticals and specialty products, agreed to acquire Advanced Diabetes Supply, a distributor of specialized diabetes supplies, from Court Square Capital Partners, a private equity firm, for $1.1bn. You can submit deals you were involved with here: https://lnkd.in/d_Firwmh "We couldn't be more excited about joining Cardinal Health at-Home Solutions to build on our mission of being a trusted partner in this critical space of the healthcare industry. It's clear that we both share the same passion of making sure the patients we serve have the best possible outcomes. Together, we can bring more simplicity, speed and quality to patients living with diabetes and the providers who care for them," William Mixon, Advanced Diabetes Supply CEO. Advanced Diabetes Supply is led by William Mixon, Mark Howard, Tim Cady and Bart Witteveen. Cardinal Health (led by Jason M. Hollar, Aaron Alt, Steve Mason and Jessica Mayer) is advised by Bank of America, Citi, J.P. Morgan, DLA Piper and Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates. Court Square Capital Partners (led by Jeff Abramoff) is advised by Houlihan Lokey, MTS Health Partners, Baird, Winston & Strawn LLP and Edelman. #MergersAcquisitionsDivestitures #HealthCare #PrivateEquity

Cardinal Health, a distributor of pharmaceuticals and specialty products, agreed to acquire a 71% stake in GI Alliance, a provider of comprehensive gastrointestinal care services, from Apollo, a private equity firm, for $2.8bn. You can submit deals you were involved with here: https://lnkd.in/d_Firwmh "Cardinal Health and GI Alliance are aligned in our shared vision to build a physician-led, national specialty healthcare platform that will be the preferred choice for all patients seeking dependable, high-quality care. This partnership brings together two like-minded organizations focused on delivering exceptional care and enhanced clinical and operational support for physicians that drives increased value," James Weber, GI Alliance CEO. Cardinal Health (led by Jason M. Hollar and Aaron Alt) is advised by Centerview Partners, Ropes & Gray LLP, Citi and Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates (led by Richard Witzel). Debt financing is provided by Bank of America. #MergersAcquisitionsDivestitures #PrivateEquity #HealthCare

Shardul Amarchand Mangaldas advised ERIS Lifesciences (“Eris”) on the acquisition of a majority stake in Swiss Parenterals Ltd (“SPL”) from the existing shareholders of SPL by Eris and certain individual purchasers. Post the transaction, Eris will hold 51% of the share capital of SPL while the individual purchasers, collectively, will hold approx. 19% of the share capital of SPL. The transaction augments the capability of Eris in the sterile injectables segment. The transaction team was led by Nivedita Tiwari, Partner; Devesh Pandey, Partner; Shailesh Singh, Principal Associate; and Anushka Ganguli, Associate. The financing team was led by Shilpa Mankar Ahluwalia, Partner; Shubhangi Garg, Partner; Utsav Dubey, Principal Associate; Purva Anand, Associate; and Gunjan Shrivastav, Associate. Tax team was led by Gouri Puri, Partner and Rahul Yadav, Counsel. Ritwik Bhattacharya, Partner advised on the competition law aspects. Read more about the transaction here - https://lnkd.in/gUaA6eFv #acquisition #shareholders #eris #lifesciences #lawfirm

Following Up on the Big 3 mention from yesterday. Drug Channels Institute, an HMP Global company released their updated assessment on were the volume lies in the PBM space for 2023. 2023 did see a lot of growth and movement in the PBMs not on this list at all. Most midmarket, transparent PBMs I have spoken to exceed their own growth goals significantly and earlier in the year than anticipated. But the Big 3 are still the Big 3: 💰 CVS Caremark: 34% 💰 ESI: 23% 💰 OptumRx: 22% May not be popular, but the chatter in recent weeks that everyone needs to leave the Big 3, it isn't realistic for all. First, where are they all going to go? We have a lot of new PBMs all looking for business, but none of them can step in a take the same level of business as the Big 3. More infrastructure is also needed at other options to support the largest clients the Big 3 have. Second, based on their utilization some would actual pay more to move away, despite what their personal feelings may be on pricing models. What is important is that plan sponsors are working with skilled consultants to ensure they are assessing and understanding all of their options so they can make informed decisions in a #transparent way. It is important that those consultants bring all of the options to the table. That is where Innovative Rx Strategies comes in. #Pharmacists #Pharmacybenefits #PBM #PBMs #Spreadpricing #Big3 #tranparency

Only put off until tomorrow what you are willing to die having left undone. Retail Sentiment Dips to 'Bullish' on Inovio Pharma Stock Summary: Last week, retail sentiment on Inovio Pharma stock experienced a slight dip from 'extremely bullish' to 'bullish.' This shift in sentiment suggests that investors are still optimistic about the company's future, although not as overwhelmingly so as before. Inovio Pharma is a healthcare company that specializes in developing innovative medical solutions. Despite the slight downturn in sentiment, the stock remains an attractive investment option for those looking to grow their Health Savings Account (HSA) portfolios. Inspirational Tone - Act Now to Avoid the Fear of Missing Out! As an investor focused on maximizing your HSA growth, it's important to stay ahead of market trends and opportunities. Don't let the fear of missing out (FOMO) hold you back from taking action and potentially benefiting from promising investment prospects like Inovio Pharma stock. By carefully analyzing market sentiments and diligently managing your portfolio, you can make informed decisions that align with your financial goals and secure a healthier financial future for yourself and your family. Embrace the power of investing in healthcare and wellness, ensuring a prosperous tomorrow. Take charge of your HSA investments today! 💪📈💼 #hsa #investing #healthcare #health #family #wellness

💰 Another busy day on Wall Street! Let's break down some of the key takeaways from today's earnings reports. Cummins Inc. $CMI - Revenue: 8.46B vs 8.29B - EPS: $5.60 vs $4.80 Grocery Outlet holding $GO - Revenue: 1.11B vs 1.10B - EPS: $0.28 vs $0.27 Fresenius Medical Care $FMS - Revenue: $5.23B vs $5.32B - EPS: $0.45 vs $0.38 Exact Sciences $EXAS - Revenue: $708.65M vs 717.66M - EPS: -$0.21 vs -$0.21 Dupont de Nemours $DD - Revenue: $3.19B vs $3.20B - EPS: $1.18 vs $1.03 Globus Medical $GMED - Revenue: $625.71M vs $603.93M - EPS: $0.83 vs $0.65 Coupang $CPNG - Revenue: $7.87B vs 7.76B - EPS: $0.06 vs $0.01 Beam Therapeutics $BEAM - Revenue: $14.27M vs $14.50M - EPS: $1.16 vs $1.17 Masimo $MASI - Revenue: $504.60M vs $502.76M - EPS: $0.98 vs $0.84

# Only put off until tomorrow what you are willing to die having left undone ## Take action now and unlock the potential of your HSA investment! Don't miss out on this opportunity! 🌟💪💼 Catalent CTLT, a leading pharmaceutical services company, has recently announced a significant development in its business operations. The company has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena, a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Netherlands, and Sweden. This strategic move by Catalent represents a pivotal step in streamlining its operations and focusing on core areas of growth. The agreement marks a substantial milestone for both Catalent and Ardena, as it opens new avenues for expansion and enhances their respective positions in the pharmaceutical industry. By divesting its facility, Catalent aims to optimize its resources and capitalize on emerging opportunities. The transaction is expected to close soon, presenting investors with an extraordinary chance to capitalize on the changes taking place in this dynamic sector. Investing in healthcare, especially through Health Savings Accounts \(HSAs\), has emerged as a powerful tool for individuals and families seeking financial security while ensuring their well-being. HSAs offer tax advantages and the ability to invest funds for long-term growth, making them an ideal vehicle to secure your future and safeguard your loved ones' health. Don't let the Fear of Missing Out \(FOMO\) hold you back from taking action. Seize this moment and explore the vast potential of HSA investing in the healthcare industry. Empower yourself by leveraging the power of healthcare investments to strengthen your financial portfolio and protect your family's well-being. #hsa #investing #healthcare #health #family #wellness 🚀✨💼🔒💰

The most successful #MSL strategy is one that aligns #HCP insights to internal business goals. Understanding HCP backgrounds, activities and priorities makes it easier to build a solid territory business plan. Katie Shin incorporated H1’s HCP data into her territory planning to create an individualized strategy for her team at Sumitomo Pharma America, Inc. Watch here: https://hubs.la/Q02YVlnZ0 You can learn more about HCP Universe here: https://hubs.la/Q02YVmz50 #sumitomo #smpa #territorymapping #mslterritoryplanning #hcpdata #hcpinsights

🌟 Diversify your portfolio with a healthcare heavyweight! CSL Ltd shares are making a strong case for investors seeking both growth avenues and appreciating dividends in this dynamic sector. With CSL Behring and Seqirus as frontline contenders in the blood plasma and vaccine space, and the recent strategic acquisition of CSL Vifor, CSL's footprint in healthcare is expansive. Despite market fluctuations, the company’s resilience is visible, with stock prices bouncing back impressively. Analysts are applauding CSL’s management and predict dividend growth and potential earnings surprises ahead. 📈 Given the current trailing yield of 1.4% and market confidence, now might be an opportune time to consider CSL for your investment mix. Does the prospect of sustainable growth coupled with stable dividends in the burgeoning healthcare market interest you? Delve into the full insights and make an informed decision. 💼🩺 Read more: https://lnkd.in/g6Ddy7D3 #Investment #HealthcareSector #CSL #Dividends #GrowthProspects #PortfolioDiversification

Increasing demand for specialized medications and personalized patient care are driving rapid growth in the specialty pharmacy space. Join this week’s Office Hours guest Derek Taylor, Senior Director, Client Services, Infinx, as he provides insights and tools necessary for success in the burgeoning world of specialty pharma. Attendees can expect to: ✅ Understand the current landscape and future trends of the specialty pharma industry. ✅ Learn about the unique resources and support options that are vital for navigating the complexities of specialty pharmacy operations effectively. ✅ Discover the specialized tools, technologies, and strategies that can drive operational excellence and competitive advantage. Whether you're a seasoned professional looking to update your knowledge or new to the specialty pharma field seeking to make your mark, Derek will share the knowledge and strategies needed to excel. Register here: https://hubs.li/Q02mql550 #PatientAccess #RCMAutomation #PriorAuthorization #SpecialtyPharmacy #SpecialtyPharma